Skip to main content

Table 3 Mechanistic studies: Urinary biochemistries in established AKI cases versus healthy controls

From: Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences

  AKI patients n available Healthy controls n available T-test P ANOVA P† Wilcoxon rank P
Urine kallikrein (U/gm creatinine) 6.74 ± 1.92 18 0.63 ± 0.08 37 0.0058 0.00029 0.0012
Urine aldosterone (pg/mg creatinine) 9269.9 ± 2652.31 16 12982.4 ± 2619.78 38 0.325 0.65 0.1282
Urine epinephrine (ng/mg creatinine) 20.1 ± 2.4 14 7.48 ± 1.07 32 1.11E-06 0.00016 1.79E-05
Urine norepinephrine, (ng/mg creatinine) 37.15 ± 8.14 14 26.85 ±
3.2
32 0.344 0.16 0.4424
Urine kallikrein/urine aldosterone ratio (mU/μg) 872.0 ± 277.5 15 160.5 ±
76.7
38 0.00027 8.45E-05 3.62E-05
Urine kallikrein/urine epinephrine ratio (mU/ng) 0.32 ± 0.13 13 0.18 ±
0.04
31 0.8465 0.8 0.899
  1. Plus-minus values are covariate-adjusted mean ± one SEM. N is the number of study subjects available to conduct each experiment. †Results are analyzed by one-way ANOVA, factoring for age, sex and race. Bold: p ≤ 0.05.